Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What is a Nervous System?01:25

What is a Nervous System?

104.3K
Overview
104.3K
The Parasympathetic Nervous System01:14

The Parasympathetic Nervous System

115.1K
Overview
115.1K
The Sympathetic Nervous System01:25

The Sympathetic Nervous System

103.1K
Overview
103.1K
The Central Dogma01:25

The Central Dogma

139.0K
Overview
139.0K
The Central Dogma01:20

The Central Dogma

32.4K
The central dogma explains the flow of genetic information from DNA nucleotides to the amino acid sequence of proteins.
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
32.4K
Nervous System01:21

Nervous System

3.4K
The nervous system coordinates body functions through its complex network of nerve cells, enabling sensation and movement. It is divided into two primary parts: the central nervous system (CNS) and the peripheral nervous system (PNS). The CNS is composed of the brain and the spinal cord. The brain acts as the body's control center, processing sensory information and coordinating responses. The spinal cord functions as a major signaling pathway for the brain and the rest of the body.
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma.

Future oncology (London, England)·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study.

Blood·2026
Same author

Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors.

Neuro-oncology advances·2026
Same author

Primary infliximab failure in pediatric colonic inflammatory bowel disease: Development of a proteomics predictive model using a prospective Canadian cohort.

Inflammatory bowel diseases·2026
Same author

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma.

Neuro-oncology·2025
Same journal

Isolated Cranial Tremors: A Reappraisal.

Seminars in neurology·2026
Same journal

Dystonia and Tremor.

Seminars in neurology·2026
Same journal

Pendular nystagmus and oculopalatal tremor.

Seminars in neurology·2026
Same journal

Sanjay Pandey, MBBS, MD, DNB, DM, FIAN, and Aasef Shaikh, MD, PhD.

Seminars in neurology·2026
Same journal

Tremor.

Seminars in neurology·2026
Same journal

Carotid Disease.

Seminars in neurology·2026
See all related articles

Related Experiment Video

Updated: Jan 22, 2026

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY
10:28

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY

Published on: June 30, 2016

14.0K

Primary Central Nervous System Lymphoma.

Sarah Löw1, Tracy T Batchelor2

  • 1Neurology Clinic and National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.

Seminars in Neurology
|March 17, 2018
PubMed
Summary
This summary is machine-generated.

Primary central nervous system lymphoma (PCNSL) is a rare brain cancer. Current treatments show limited survival, highlighting the need for novel therapeutic strategies against PCNSL.

More Related Videos

Culturing Microglia from the Neonatal and Adult Central Nervous System
11:28

Culturing Microglia from the Neonatal and Adult Central Nervous System

Published on: August 9, 2013

28.8K
Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE
20:51

Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE

Published on: December 3, 2007

16.7K

Related Experiment Videos

Last Updated: Jan 22, 2026

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY
10:28

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY

Published on: June 30, 2016

14.0K
Culturing Microglia from the Neonatal and Adult Central Nervous System
11:28

Culturing Microglia from the Neonatal and Adult Central Nervous System

Published on: August 9, 2013

28.8K
Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE
20:51

Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE

Published on: December 3, 2007

16.7K

Area of Science:

  • Oncology
  • Neurology
  • Immunology

Background:

  • Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma affecting the brain, spinal cord, leptomeninges, and eyes.
  • Typically diagnosed in individuals around 65 years old, most patients are immunocompetent.
  • Whole-brain radiation therapy (WBRT), once standard, is now often avoided due to neurotoxicity.

Purpose of the Study:

  • To review the current treatment landscape for PCNSL.
  • To discuss emerging therapeutic strategies aimed at improving patient outcomes.
  • To highlight the limitations of existing treatments and the need for advancements.

Main Methods:

  • Literature review of PCNSL treatment modalities.
  • Analysis of current chemotherapy regimens, including high-dose methotrexate and rituximab.
  • Exploration of novel approaches such as stem cell transplantation, targeted therapies, and immunotherapy.

Main Results:

  • High-dose methotrexate plus rituximab yields high response rates but a poor 5-year survival rate of approximately 30%.
  • Existing treatments face challenges in significantly improving long-term survival compared to other extranodal lymphomas.
  • New strategies are under investigation to overcome current therapeutic limitations.

Conclusions:

  • Despite advances, PCNSL remains a challenging diagnosis with suboptimal long-term survival.
  • Novel treatment strategies, including targeted therapies and immunotherapy, hold promise for improving PCNSL outcomes.
  • Further research is crucial to develop more effective treatments for primary central nervous system lymphoma.